OncoMatch/Clinical Trials/NCT06378346
GU-01: Glycyrrhizin in Prostate Cancer
Is NCT06378346 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Glycyrrhizin - 75 mg and Glycyrrhizin - 150 mg for prostate cancer.
Treatment: Glycyrrhizin - 75 mg · Glycyrrhizin - 150 mg — This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: biological therapy
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: radiation therapy
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: androgen
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: immunotherapy
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: other anticancer agents (thalidomide)
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Cannot have received: investigational agent
Exception: within 30 days of starting study treatment
Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify